EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Rituximab treatment in pediatric‐onset multiple sclerosis

Markus Breu iD, Fredrik Sandesjö iD, Ruxandra-Iulia Milos, Jan Svoboda iD, Jonatan Salzer iD, Lisa Schneider, Julian Benedikt Reichelt, Annikki Bertolini, Astrid Blaschek, Katharina Fink iD, Romana Höftberger, Jan Lycke und 5 weitere

European Journal of Neurology · 2024-05 · 31 (5)

DOI: 10.1111/ene.16228 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Neurology, online erschienen am 20.02.2024. Verfasst von Markus Breu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vie…. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: StratNeuro, Karolinska Institutet, Stiftelsen Sunnerdahls Handikappfond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Rituximab (RTX) is frequently used off‐label in multiple sclerosis. However, studies on the risk–benefit profile of RTX in pediatric‐onset multiple sclerosis are scarce.

Methods

In this multicenter retrospective cohort study, patients with pediatric‐onset multiple sclerosis from Sweden, Austria and Germany, who received RTX treatment were identified by chart review. Annualized relapse rates, Expanded Disability Status Scale scores and magnetic resonance imaging parameters (new T2 lesions and contrast‐enhancing lesions) were assessed before and during RTX treatment. The proportion of patients who remained free from clinical and disease activity (NEDA‐3) during RTX treatment was calculated. Side effects such as infusion‐related reactions, infections and laboratory abnormalities were assessed.

Results

Sixty‐one patients received RTX during a median (interquartile range) follow‐up period of 20.9 (35.6) months. The annualized relapse rate decreased from 0.6 (95% confidence interval [CI] 0.38–0.92) to 0.03 (95% CI 0.02–0.14). The annual rate of new T2 lesions decreased from 1.25 (95% CI 0.70–2.48) to 0.08 (95% CI 0.03–0.25) and annual rates of new contrast‐enhancing lesions decreased from 0.86 (95% CI 0.30–3.96) to 0. Overall, 70% of patients displayed no evidence of disease activity (NEDA‐3). Adverse events were observed in 67% of patients. Six patients discontinued treatment due to ongoing disease activity or adverse events.

Conclusion

Our study provides class IV evidence that RTX reduces clinical and radiological activity in pediatric‐onset multiple sclerosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingChildHumansRituximabImmunologic FactorsRetrospective StudiesRecurrence

Stichwörter der Autor:innen

central nervous systemcohort studydisease‐modifying therapypediatric‐onset multiple sclerosisrituximab

Substanzen

RituximabImmunologic Factors

Autor:innen und Institutionen

  • Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
  • Neuropediatric Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
  • Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
  • Division of Infectious Diseases, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Markus Breu, Fredrik Sandesjö, Jan Svoboda, Jonatan Salzer, Katharina Fink, Barbara Kornek

Förderung

  • StratNeuro
  • Karolinska Institutet
  • Stiftelsen Sunnerdahls Handikappfond
  • Sällskapet Barnavård
  • Hjärnfonden
  • Region Stockholm

Zitieren

APA

Breu, M., Sandesjö, F., Milos, R. I., Svoboda, J., Salzer, J., Schneider, L., Reichelt, J. B., Bertolini, A., Blaschek, A., Fink, K., Höftberger, R., Lycke, J., Rostásy, K., Seidl, R., Siegert, S., Wickström, R., & Kornek, B. (2024). Rituximab treatment in pediatric‐onset multiple sclerosis. European Journal of Neurology, 31(5). https://doi.org/10.1111/ene.16228

Vancouver

Breu M, Sandesjö F, Milos RI, Svoboda J, Salzer J, Schneider L, et al. Rituximab treatment in pediatric‐onset multiple sclerosis. European Journal of Neurology. 2024;31(5). doi:10.1111/ene.16228

BibTeX
@article{Breu2024,
  author = {Breu, Markus and Sandesjö, Fredrik and Milos, Ruxandra-Iulia and Svoboda, Jan and Salzer, Jonatan and Schneider, Lisa and Reichelt, Julian Benedikt and Bertolini, Annikki and Blaschek, Astrid and Fink, Katharina and Höftberger, Romana and Lycke, Jan and Rostásy, Kevin and Seidl, Rainer and Siegert, Sandy and Wickström, Ronny and Kornek, Barbara},
  title = {Rituximab treatment in pediatric‐onset multiple sclerosis},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {5},
  doi = {10.1111/ene.16228}
}
Kostenlos starten →